BMS
Integrated Tumor, Microbiome Features Influence Immunotherapy Combo Effects in Advanced Melanoma
Gut microbiome features showed ties to treatment response and immune-related adverse events in advanced melanoma patients on a combined checkpoint blockade treatment.
Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance
Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.
Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.